Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
Keywords: ارلوتینیب; Ovarian cancer; Bevacizumab; Erlotinib